First & Free – a hemp-derived CBD product line
Canopy Growth (NYSE:CGC) has launched First & Free – a hemp-derived CBD product line offered in a variety of formats, including softgels, oil drops and creams. The products will be available for purchase through e-commerce site: www.firstandfree.com.
Recreational marijuana legal in Illinois
Illinois is ringing in the new decade by becoming the 11th state in the country and the District of Columbia to allow the legal sale and purchase of marijuana.
Under the new state law, adults over the age of 21 may own 30 grams of cannabis flower, 500 milligrams of THC in pot products and 5 grams of cannabis concentrate.
Cannabis stocks are enjoying end-of-the-year buying today, giving battered longs hope for a better 2020. Selected tickers: Cronos Group (CRON +11.7%), Aurora Cannabis (ACB +11.3%), Tilray (TLRY +8.5%), Canopy Growth (CGC +9.2%), Alternative Harvest ETF (MJ +4.3%), The Cannabis ETF (THCX +4%), Aphria (APHA +7%)
Crystal Coma is a rare sativa-dominant hybrid from California that induces deep, trance-like effects. Its name foreshadows the debilitating relaxation to come, a long-lasting calm that shuts off mental overactivity. Pastel green breaks through this sativa’s thick blanket of crystal trichomes that contributes to its staggeringly high THC content of up to 26 percent.
Cannabidiol is a chemical in the Cannabis sativa plant, also known as marijuana or hemp. Over 80 chemicals, known as cannabinoids, have been identified in the Cannabis sativa plant. While delta-9-tetrahydrocannabinol (THC) is the major active ingredient in marijuana, cannabidiol is also obtained from hemp, which contains only very small amounts of THC.
Cannabidiol has effects on the brain. The exact cause for these effects is not clear. However, cannabidiol seems to prevent the breakdown of a chemical in the brain that affects pain, mood, and mental function. Preventing the breakdown of this chemical and increasing its levels in the blood seems to reduce psychotic symptoms associated with conditions such as schizophrenia. Cannabidiol might also block some of the psychoactive effects of delta-9-tetrahydrocannabinol (THC). Also, cannabidiol seems to reduce pain and anxiety.
Our Charlotte’s Web™ CBD hemp extract gummies are formulated with our full-spectrum hemp extract and contain 10 mg of CBD hemp extract and 3 mg of melatonin in every serving to help you float off to dreamland.
Charlotte’s Web™ CBD oil products include whole-plant hemp extracts from Charlotte’s Web™ plants. The extracts contain a unique blend of cannabinoids plus terpenes and flavonoids. Cannabinoids are phytocompounds that are produced by the hemp plant.
The management team at Canopy Growth revealed some really positive developments, but also some very painful ones incurred by the business.
In its latest quarter, the company posted a record harvest that indicates strong sales moving forward. However, pricing, declining cash balances, and continued negative cash flows are all concerns that investors need to keep in mind.
Pain just keeps building up for the players in the cannabis space. In its latest filing, for instance, the management team at Canopy Growth Corp. (CGC) revealed that, despite posting strong sales and volume growth in the first quarter of its 2020 fiscal year, it’s still unable to generate a profit.
Add to this continued declines in its cash on hand, poor recreational cannabis pricing, and the prospect of some industry oversupply issues, and investors are right to be concerned. Even though, in the long run, Canopy will likely dominate the space as one of the few major players in the market, in the short run it looks like shareholders could be in for a world of hurt if current trends continue.
Management did say that during the quarter they happened to harvest 40,960kg of the plant, up 323% from the 9,685kg harvested one year earlier. The amount actually harvested during the quarter was well above the 34,000kg worth previously forecasted, and over 70% of what was produced fits the company’s definition of “high THC” strains. This should translate into far higher sales in the next quarter or two, meaning that this prior quarter may have been more of a bump in the road on Canopy’s road to growth.
This Friday, May 31, the FDA will host a public hearing aimed at gathering scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of cannabis-containing products and cannabis-derived compounds. The agency’s objective is to clarify a workable regulatory framework for the products since the cultivation and production of hemp was legalized in the 2018 Farm Bill.
A docket for public comment, FDA-2019-N-1482, will be available until July 2.
Acquiring “Select”, the Leading Cannabis Wholesale Brand in the U.S.
Curaleaf Holdings (OTCPK:CURLF) announces a deal to purchase the the cannabis business of Cura Partners (owners of the Select brand) in an all-stock deal valued at just under $1B. Brings together two of the most well-known, fastest growing cannabis brands on the East Coast and West Coast
Combines the largest retail operator and the highest revenue generating wholesaler in the U.S., achieving significant operational synergies. Accelerates growth, diversifies product range and expands customer reach and accessibility
Natural, Organic Cold Brew & Energy Teas
Guided by Bob’s vision to live consciously and purposefully, we strategically crafted a lineup of canned, all-natural, and organic cold coffees and teas that embody the Marley values of authenticity and living naturally. Situated at the intersection of an active, creative lifestyle and the emergent health movement, Marley beverages are driven to fuel the personal growth of those they reach. Join us in inspiring mindful, healthy living. One Love.
Receives Fast Track Designation for Zygel™
DEVON, Pa., May 06, 2019 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company’s lead development candidate Zygel™ (ZYN002 CBD gel) for treatment of behavioral symptoms associated with Fragile X Syndrome (FXS). FDA’s Fast Track program is designed to facilitate the development of drugs intended to treat serious conditions and fill unmet medical needs, and can lead to expedited review by FDA in order to get new important drugs to the patient earlier.
About Fast Track Designation
Fast Track Designation is intended to facilitate development and expedite review of drugs to treat serious or life-threatening conditions so that a product can reach the market expeditiously. A drug that is intended to treat a serious or life-threatening condition that demonstrates the potential to address an unmet medical need may qualify for Fast Track designation. Features of this designation include opportunities for frequent interactions with the review team. These include meetings with the FDA to discuss items such as study design, extent of safety data required to support approval, dose-response concerns, accelerated approval, the structure and content of an NDA, and other critical issues. In addition, such a product could be eligible for priority review if supported by clinical data at the time of NDA.